Bharat Parenterals FY26: A Flat Headline, A Changing Mix

Bharat Parenterals Limited closed FY26 with consolidated revenue from operations of ₹345.4 crore, up slightly from ₹340.0 crore in FY25. The headline number looks steady, but management described FY26 as a transition year where the group completed a deliberate investment phase and prepared for a commercial inflection in FY27.

Profitability improved at the operating line even though the bottom line remained negative. Consolidated EBITDA rose to ₹15.8 crore from ₹2.7 crore in FY25, and the consolidated PAT loss narrowed to ₹27.3 crore from ₹43.7 crore.

The shift came from within the portfolio. The standalone export-led formulations business had a weak year, while Inoxel Lifesciences scaled milestone-led revenue sharply and moved to EBITDA-positive in Q4. The domestic institutional business, Varenyam Healthcare, grew and turned profitable at a full-year level.

FY26 financial summary: consolidated and by entity

In FY26, the standalone parent business (BPL) reported revenue from operations of ₹234 crore, down 23.1% year on year. Inoxel Lifesciences reported ₹72.4 crore, up 174.1% year on year, largely driven by licensing and milestone income. Varenyam Healthcare delivered ₹58.4 crore, up 13.7% year on year.

Consolidated EBITDA margin was 4.6% for FY26, while consolidated PAT margin remained negative at 7.9%.

Standalone BPL: disruption-led softness, upgrades for audits

Management was direct about the standalone decline. Revenue dropped because export tenders were deferred into the next year, the company chose to exit certain low-margin volumes, and several production lines were taken down for upgradation work.

The upgrades included work on the general injectable vial line, a new water system in the beta-lactam block, and structural changes in preparation for EU-GMP. Management also flagged that FY27 will see two major audit events for the standalone facilities, PIC/S and EU-GMP, which could create disruption during preparation and inspection.

Even with lower revenue, the standalone business delivered FY26 EBITDA of ₹21.1 crore at a 9% margin and PAT of ₹16 crore. However, Q4 showed how sensitive earnings can be when utilization drops. Q4 standalone EBITDA was only ₹0.03 crore, with a near-zero margin.

Operationally, the company highlighted filings momentum and headroom in capacity. FY26 included 214 dossiers submitted and 48 new product registrations. Utilization levels were stated as 48.5% in the General block, 21% in Beta-Lactam, and 24.3% in Cephalosporin, indicating room to scale without major incremental capex. The order book was disclosed at ₹171 crore.

Inoxel Lifesciences: regulatory clearances and the early turn

Inoxel is the group’s regulated-market platform built around complex and specialty injectables, with a business model that includes out-licensing and CDMO and CMO partnerships.

FY26 was positioned as the regulatory breakthrough year. Inoxel received the USFDA Establishment Inspection Report for an inspection conducted from Apr 28 to May 2, 2025. It also completed an EU-GMP inspection by Belgium’s FAMHP with zero critical or major observations. Management said these approvals enable commercial supply to the US and select European markets.

Financially, Inoxel narrowed losses materially. FY26 EBITDA loss improved to ₹6.9 crore from ₹30.4 crore in FY25. In Q4 FY26, Inoxel delivered EBITDA of ₹1.4 crore, turning EBITDA-positive for the first time. Revenue in Q4 was ₹37.5 crore, contributing to a sharp sequential improvement in consolidated revenue.

Management disclosed FY26 deal activity as a key leading indicator. Inoxel signed 23 deals in FY26, with 7 out-licensing and 16 CMO and CDO engagements, and reported 19 active partners across the US, EU, and India. The FY26 cumulative licensing revenue was ₹72.4 crore.

Varenyam Healthcare: growth with operating leverage, but quarter volatility

Varenyam Healthcare is the group’s domestic institutional branded generics business, selling into hospitals across India. FY26 revenue rose to ₹58.4 crore from ₹51.4 crore. The meaningful change was profitability. FY26 EBITDA was ₹2.5 crore versus a loss in FY25, and FY26 PAT was ₹2.3 crore versus a loss in FY25.

Management attributed the operating leverage to improving productivity and wider coverage. Medical representative strength increased from 190 to 211 during FY26, with a target of 250 by FY27. PCPM was stated at ₹3.82 lakh per MR per month, up 31% year on year.

Brand concentration is material. The top five brands contributed ₹28.68 crore, or 49.4% of FY26 revenue. The largest brand, Sugmadex, contributed ₹10.23 crore, or 17.5%.

Quarterly performance was uneven. Q4 FY26 revenue fell to ₹11.6 crore and EBITDA turned negative at ₹1.5 crore, while management described Q4 as structurally softer for the institutional channel.

Varenyam Bio: long-dated capex with FY29 supply timeline

Varenyam Bio Lifesciences remains pre-revenue. The company disclosed FY26 CWIP of ₹32.26 crore, about 20.2% of the ₹160 crore budget. Commissioning is targeted for Sep 2027, validation by Mar 2028, first filing in Q1 FY29, and first commercial supply by Q4 FY29.

This timeline matters because it implies continued losses and cash requirements through the build phase, even as the group expects FY27 to be the commercial inflection for the other three operating businesses.

FY27 guidance: ranges, not point estimates

Management provided business-wise ranges for FY27:

• BPL standalone: 10 to 15% revenue growth and 10 to 15% EBITDA margin
• Inoxel: 35 to 45% revenue growth and 20 to 25% EBITDA margin, with out-licensing and milestone income expected at ₹70 to ₹90 crore
• Varenyam Healthcare: 20 to 25% revenue growth and 8 to 13% EBITDA margin
• Varenyam Bio: pre-revenue and loss-making

Management also acknowledged being more cautious with guidance after earlier misses, stating a preference for ranges they expect to achieve.

Takeaways

FY26 did not deliver growth at the consolidated revenue line, but it did show a clear portfolio transition. The standalone export business absorbed disruption from upgrades and delayed tenders. Inoxel delivered regulatory clearances and a sharp improvement in EBITDA, including a first EBITDA-positive quarter. Varenyam Healthcare grew and turned profitable for the full year, though quarter volatility remains.

FY27 execution will hinge on two moving parts: the scale-up of Inoxel commercial supply alongside milestone income, and the standalone business navigating PIC/S and EU-GMP readiness without prolonged operational disruption. The group’s own framing is clear. FY26 was the bridge year. FY27 is expected to test whether the new mix can translate into sustained profitability.